Industrial - Distribution
Build Your Comparison
Side-by-side financial analysisStock Comparison
TRNS vs TMO vs DHR vs A
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
TRNS vs TMO vs DHR vs A — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Industrial - Distribution | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $852M | $174.42B | $127.47B | $36.67B |
| Revenue (TTM) | $333M | $45.20B | $24.78B | $7.23B |
| Net Income (TTM) | $7M | $6.86B | $3.69B | $1.41B |
| Gross Margin | 32.6% | 39.4% | 60.7% | 53.0% |
| Operating Margin | 4.1% | 17.8% | 21.0% | 21.5% |
| Forward P/E | 51.9x | 18.9x | 21.3x | 21.4x |
| Total Debt | $129M | $40.85B | $18.42B | $3.35B |
| Cash & Equiv. | $5M | $9.86B | $4.62B | $1.79B |
TRNS vs TMO vs DHR vs A — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Transcat, Inc. (TRNS) | 100 | 352.9 | +252.9% |
| Thermo Fisher Scien… (TMO) | 100 | 129.5 | +29.5% |
| Danaher Corporation (DHR) | 100 | 114.9 | +14.9% |
| Agilent Technologie… (A) | 100 | 146.9 | +46.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TRNS vs TMO vs DHR vs A
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TRNS has the current edge in this matchup, primarily because of its strength in growth exposure and long-term compounding.
- Rev growth 19.2%, EPS growth -63.7%, 3Y rev CAGR 12.9%
- 7.7% 10Y total return vs TMO's 219.0%
- 19.2% revenue growth vs DHR's 2.9%
- +17.9% vs DHR's -11.5%
TMO is the clearest fit if your priority is value.
- Lower P/E (18.9x vs 51.9x)
DHR is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 9 yrs, beta 0.70, yield 0.7%
- Lower volatility, beta 0.70, Low D/E 35.1%, current ratio 1.87x
- Beta 0.70 vs TRNS's 1.35, lower leverage
- 0.7% yield, 9-year raise streak, vs A's 0.8%, (1 stock pays no dividend)
A is the clearest fit if your priority is valuation efficiency and defensive.
- PEG 1.46 vs DHR's 35.21
- Beta 1.06, yield 0.8%, current ratio 1.96x
- 19.6% margin vs TRNS's 2.0%
- 11.1% ROA vs TRNS's 1.4%, ROIC 13.5% vs 2.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.2% revenue growth vs DHR's 2.9% | |
| Value | Lower P/E (18.9x vs 51.9x) | |
| Quality / Margins | 19.6% margin vs TRNS's 2.0% | |
| Stability / Safety | Beta 0.70 vs TRNS's 1.35, lower leverage | |
| Dividends | 0.7% yield, 9-year raise streak, vs A's 0.8%, (1 stock pays no dividend) | |
| Momentum (1Y) | +17.9% vs DHR's -11.5% | |
| Efficiency (ROA) | 11.1% ROA vs TRNS's 1.4%, ROIC 13.5% vs 2.6% |
TRNS vs TMO vs DHR vs A — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TRNS vs TMO vs DHR vs A — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
A leads in 2 of 6 categories
DHR leads 1 • TRNS leads 1 • TMO leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
A leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 135.9x TRNS's $333M. A is the more profitable business, keeping 19.6% of every revenue dollar as net income compared to TRNS's 2.0%. On growth, TRNS holds the edge at +15.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $333M | $45.2B | $24.8B | $7.2B |
| EBITDAEarnings before interest/tax | $40M | $10.5B | $7.2B | $1.8B |
| Net IncomeAfter-tax profit | $7M | $6.9B | $3.7B | $1.4B |
| Free Cash FlowCash after capex | $20M | $6.7B | $5.3B | $1.3B |
| Gross MarginGross profit ÷ Revenue | +32.6% | +39.4% | +60.7% | +53.0% |
| Operating MarginEBIT ÷ Revenue | +4.1% | +17.8% | +21.0% | +21.5% |
| Net MarginNet income ÷ Revenue | +2.0% | +15.2% | +14.9% | +19.6% |
| FCF MarginFCF ÷ Revenue | +5.9% | +14.9% | +21.4% | +17.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.8% | +6.2% | +3.7% | +10.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.3% | +11.3% | +9.8% | +60.0% |
Valuation Metrics
DHR leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 26.5x trailing earnings, TMO trades at a 83% valuation discount to TRNS's 160.1x P/E. Adjusting for growth (PEG ratio), A offers better value at 1.93x vs DHR's 35.21x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $852M | $174.4B | $127.5B | $36.7B |
| Enterprise ValueMkt cap + debt − cash | $976M | $205.4B | $141.3B | $38.2B |
| Trailing P/EPrice ÷ TTM EPS | 160.11x | 26.46x | 35.73x | 28.41x |
| Forward P/EPrice ÷ next-FY EPS est. | 51.85x | 18.88x | 21.34x | 21.43x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.53x | 35.21x | 1.93x |
| EV / EBITDAEnterprise value multiple | 24.76x | 18.86x | 18.63x | 21.64x |
| Price / SalesMarket cap ÷ Revenue | 2.57x | 3.91x | 5.19x | 5.28x |
| Price / BookPrice ÷ Book value/share | 2.83x | 3.31x | 2.44x | 5.47x |
| Price / FCFMarket cap ÷ FCF | 43.60x | 27.72x | 24.23x | 31.83x |
Profitability & Efficiency
A leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
A delivers a 20.8% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $2 for TRNS. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs A's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.2% | +13.2% | +7.1% | +20.8% |
| ROA (TTM)Return on assets | +1.4% | +6.4% | +4.5% | +11.1% |
| ROICReturn on invested capital | +2.6% | +7.5% | +5.9% | +13.5% |
| ROCEReturn on capital employed | +3.3% | +9.1% | +7.0% | +14.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.43x | 0.76x | 0.35x | 0.50x |
| Net DebtTotal debt minus cash | $124M | $31.0B | $13.8B | $1.6B |
| Cash & Equiv.Liquid assets | $5M | $9.9B | $4.6B | $1.8B |
| Total DebtShort + long-term debt | $129M | $40.9B | $18.4B | $3.4B |
| Interest CoverageEBIT ÷ Interest expense | 2.81x | 5.89x | 18.13x | 15.72x |
Total Returns (Dividends Reinvested)
TRNS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TRNS five years ago would be worth $16,632 today (with dividends reinvested), compared to $8,449 for DHR. Over the past 12 months, TRNS leads with a +17.9% total return vs DHR's -11.5%. The 3-year compound annual growth rate (CAGR) favors A at 3.8% vs DHR's -4.5% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +59.7% | -20.7% | -21.7% | -5.5% |
| 1-Year ReturnPast 12 months | +17.9% | +13.4% | -11.5% | +10.0% |
| 3-Year ReturnCumulative with dividends | -1.0% | -9.5% | -13.0% | +12.0% |
| 5-Year ReturnCumulative with dividends | +66.3% | +1.4% | -15.5% | -6.9% |
| 10-Year ReturnCumulative with dividends | +769.1% | +219.0% | +222.6% | +206.2% |
| CAGR (3Y)Annualised 3-year return | -0.3% | -3.3% | -4.5% | +3.8% |
Risk & Volatility
Evenly matched — TRNS and DHR each lead in 1 of 2 comparable metrics.
Risk & Volatility
DHR is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than TRNS's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TRNS currently trades 96.3% from its 52-week high vs TMO's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.35x | 0.91x | 0.70x | 1.06x |
| 52-Week HighHighest price in past year | $94.76 | $643.99 | $242.80 | $160.27 |
| 52-Week LowLowest price in past year | $50.23 | $385.46 | $160.93 | $108.35 |
| % of 52W HighCurrent price vs 52-week peak | +96.3% | +72.9% | +74.2% | +81.0% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 50.8 | 52.0 | 56.1 |
| Avg Volume (50D)Average daily shares traded | 155K | 2.0M | 4.2M | 1.9M |
Analyst Outlook
Evenly matched — DHR and A each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: TRNS as "Buy", TMO as "Buy", DHR as "Buy", A as "Buy". Consensus price targets imply 35.4% upside for TRNS (target: $124) vs 19.2% for A (target: $155). For income investors, A offers the higher dividend yield at 0.76% vs TMO's 0.36%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $123.60 | $599.70 | $231.80 | $154.75 |
| # AnalystsCovering analysts | 10 | 42 | 43 | 40 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% | +0.7% | +0.8% |
| Dividend StreakConsecutive years of raises | 0 | 8 | 9 | 0 |
| Dividend / ShareAnnual DPS | — | $1.69 | $1.23 | $0.99 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +1.7% | +2.4% | +1.2% |
A leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DHR leads in 1 (Valuation Metrics). 2 tied.
TRNS vs TMO vs DHR vs A: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TRNS or TMO or DHR or A a better buy right now?
For growth investors, Transcat, Inc.
(TRNS) is the stronger pick with 19. 2% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 5x trailing P/E (18. 9x forward), making it the more compelling value choice. Analysts rate Transcat, Inc. (TRNS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TRNS or TMO or DHR or A?
On trailing P/E, Thermo Fisher Scientific Inc.
(TMO) is the cheapest at 26. 5x versus Transcat, Inc. at 160. 1x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 18. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 46x versus Danaher Corporation's 35. 21x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — TRNS or TMO or DHR or A?
Over the past 5 years, Transcat, Inc.
(TRNS) delivered a total return of +66. 3%, compared to -15. 5% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: TRNS returned +769. 1% versus A's +206. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TRNS or TMO or DHR or A?
By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.
70β versus Transcat, Inc. 's 1. 35β — meaning TRNS is approximately 92% more volatile than DHR relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — TRNS or TMO or DHR or A?
By revenue growth (latest reported year), Transcat, Inc.
(TRNS) is pulling ahead at 19. 2% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -63. 7% for Transcat, Inc.. Over a 3-year CAGR, TRNS leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TRNS or TMO or DHR or A?
Agilent Technologies, Inc.
(A) is the more profitable company, earning 18. 8% net margin versus 1. 6% for Transcat, Inc. — meaning it keeps 18. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: A leads at 21. 3% versus 4. 0% for TRNS. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TRNS or TMO or DHR or A more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 46x versus Danaher Corporation's 35. 21x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 18. 9x forward P/E versus 51. 9x for Transcat, Inc. — 33. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TRNS: 35. 4% to $123. 60.
08Which pays a better dividend — TRNS or TMO or DHR or A?
In this comparison, A (0.
8% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. TRNS does not pay a meaningful dividend and should not be held primarily for income.
09Is TRNS or TMO or DHR or A better for a retirement portfolio?
For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
70), 0. 7% yield, +222. 6% 10Y return). Both have compounded well over 10 years (DHR: +222. 6%, TRNS: +769. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TRNS and TMO and DHR and A?
These companies operate in different sectors (TRNS (Industrials) and TMO (Healthcare) and DHR (Healthcare) and A (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: TRNS is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock; DHR is a mid-cap quality compounder stock; A is a mid-cap quality compounder stock. DHR, A pay a dividend while TRNS, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.